By Bio-IT World Staff
May 29, 2015 | Definiens today launched a new suite of
Biomarker Datafication Services for oncology clinical development programs. The
package provides image analysis screening of tissue samples for exploratory screening,
pharmacokinetics/pharmacodynamics, and companion diagnostic development.
Definiens’ image analysis tools and their promise in patient
stratification and companion diagnostics were the main
driver behind AstraZeneca’s purchase of the company last November. The
pharma purchased Definiens through MedImmune, its global biologics and research
arm.
“It can be challenging to determine which biomarkers or
indications to move into clinical development,” said Merrilyn Datta, president
of Definiens, in a statement. “The Biomarker Datafication Services package is
Definiens’ solution for the clinical development market. It enables researchers
working with human tissue samples to define cutpoints for patient
stratification, such as clearly defining the complex contextual relationships
in the tumor microenvironment that are relevant to patient response. Ultimately
this tool provides researchers with better data so they can be sure they’re
moving the biomarkers and indications with the highest probability of success
into clinical trials.”
By providing high quality image analysis screening for fast
and quantitative measurement, users of the services can receive powerful data
output including biomarker expression profiles, biological response to therapy
and continuous biomarker readouts, allowing highly advanced decision making and
data analysis.
Definiens’ Biomarker Datafication Services provide
preliminary image analysis screening for fast and quantitative measurements to
compare biomarker expression profiles across indications, enabling researchers
to determine the strongest biomarker signals for clinical development and
companion diagnostics. The solution also provides quantitative image analysis
measurements of biological responses to therapy in Phase I, giving
pharmaceutical and biotech companies a thorough understanding of therapy
performance before investing in Phase II.